



⑯ Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑮ Publication number:

0 128 007  
A2

⑯

## EUROPEAN PATENT APPLICATION

⑯ Application number: 84303644.3

⑮ Int. Cl.<sup>3</sup>: C 07 D 295/12  
C 07 D 295/10, C 07 D 295/18  
//A61K31/495

⑯ Date of filing: 31.05.84

⑯ Priority: 02.06.83 JP 88713/83

⑯ Inventor: Hattori, Elzou  
2-6-21, Tsurumai  
Sakado-shi Saitama-ken(JP)

⑯ Data of publication of application:  
12.12.84 Bulletin 84/50

⑯ Inventor: Hirata, Mitsuteru  
1001, Suneori Tsurugashima-cho  
Iruma-gen Saitama-ken(JP)

⑯ Designated Contracting States:  
CH DE FR GB IT LI

⑯ Inventor: Kunieda, Hisashi  
4-6-5, Fujimi-cho  
Higashi-Murayama-shi Tokyo(JP)

⑯ Applicant: KOWA COMPANY, LTD.  
6-29, 3-chome Nishiki  
Naka-ku Nagoya-shi Aichi-ken(JP)

⑯ Inventor: Watanabe, Koichiro  
8-8-20, Nobidome  
Niiza-shi Saitama-ken(JP)


⑯ Inventor: Fujii, Setsuro  
1-4-27, Midorigaoka  
Toyonaka-shi Osaka-fu(JP)

⑯ Inventor: Ishihama, Hiroshi  
2-8-8, Suwa-cho  
Higashi-Murayama-shi Tokyo(JP)

⑯ Representative: Webb, Frederick Ronald et al,  
G.F. Redfern & Co. Marlborough Lodge 14 Farncombe  
Road  
Worthing West Sussex BN11 2BT(GB)

⑯ Phenyl tetrahydronaphthylcarboxylate derivatives.

⑯ Phenyl tetrahydronaphthylcarboxylate derivatives of the  
formula (I) and acid addition salts thereof:




wherein A is a direct bond, or a lower alkylene, vinylene or imino group; B is a direct bond, a lower alkylene or -NH-lower alkylene group, or an -OCH<sub>2</sub>CO- residual group; and R is a lower alkyl group, with the proviso that A and B are not both direct bonds, and A, B and R are not a lower alkylene group, a direct bond and a methyl group, respectively, at the same time, are effectively useful as chymotrypsin inhibitors.

A2  
007 0128 EP 0

"PHENYL TETRAHYDRONAPHTHYLCARBOXYLATE DERIVATIVES"

This invention relates to novel phenyl tetrahydro-naphthylcarboxylate derivatives, and more specifically to phenyl tetrahydronaphthylcarboxylate derivatives represented by the following formula (I); and their acid addition salts:-



wherein A is a direct bond, or a lower alkylene, vinylene or imino group; B is a direct bond, a lower alkylene or -NH-lower alkylene group, or an -OCH<sub>2</sub>CO- residual group; and R is a lower alkyl group, with the proviso that A and B are not both direct bonds, and A, B and R are not a lower alkylene group, a direct bond and a methyl group, respectively, at the same time.

Numerous phenyl esters have been previously found by the present inventors which can exert remarkable chymotrypsin inhibitory effects (Japanese Patent Laid-open Publication No. 38243/1983).


The present inventors have further synthesized a series of compounds analogous to such phenyl esters and have determined their physiological activities. Through these research efforts leading to this invention, it has been discovered that phenyl tetrahydronaphthylcarboxylates

- 2 -

of the formula (I) above and their acid addition salts have more excellent inhibitory effects on chymotrypsin.

The compounds of the formula (I) and their acid addition salts, are useful by virtue of their chymotrypsin inhibitory characteristics for various purposes, for example, as drugs for the therapy of pancreatic diseases.

Compounds of the formula (I) according to this invention can be prepared, for example, by esterifying tetrahydronaphthylcarboxylic acids of the formula (II) below with 4-substituted phenols of the formula (III) below in accordance with the following reaction scheme:



(II)

(III)

(I)

wherein the symbols A, R and R have the same meanings and restrictions, as defined

above.

The esterification reaction referred to above may be carried out by methods commonly employed in the art. One suitable method useful in the invention is to react 5 reactive derivatives of the compounds of the formula (II), such as their acid halides, acid anhydrides, mixed acid anhydrides, active esters, azides and the like, with the compounds of the formula (III). Another advantageous method involves reacting the compounds of the formula (II) 10 with the compounds of the formula (III) in the presence of a dehydrating agent such as dicyclohexylcarbodiimide, or the like.

Where it is found desirable, the thus obtained compounds of the formula (I) may be converted in 15 conventional manner to inorganic or organic acid addition salts thereof. Eligible inorganic acids include, for example, hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and like acids. Eligible organic acids include, for example, acetic acid, propionic acid, maleic 20 acid, fumaric acid, tartaric acid, oxalic acid, citric acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, and like acids.

Some selected compounds of this invention were tested with respect to their chymotrypsin inhibitory effects.

25 The tests were conducted in accordance with the procedure of Muramatsu et al [The Journal of Biochemistry, 62, 408 (1967)]. A mixture was prepared which was made up

- 4 -

of 0.1 ml of a dimethylsulfoxide solution of each test compound, 0.1 ml of water and 0.1 ml of a buffer solution containing 10  $\mu$ g/ml of chymotrypsin (0.1M Tris-HCl buffer, pH 8.0). The mixture was incubated for 10 minutes, followed by addition of 0.2 ml of a buffer solution containing 25 mM of an ethyl ester of acetyl-L-tyrosine. The resulting mixture was reacted at 37°C for 30 minutes. The remaining substrate was caused to develop a color by the Hesterin method, whereupon its absorbance was measured at 530 nm. As a comparative compound, use was made of tosylphenylalanine chloromethyl ketone (TPCK) which is known as an inhibitor for chymotrypsin.

The results are shown in Table 1 in which the numbers of the test compounds are indicated as those of the corresponding examples given hereunder.

Table 1

Test Compound	Inhibitory Activity [50% Inhibitory Concentration (M)]
1	$4 \times 10^{-6}$
2	$3 \times 10^{-6}$
3	$7 \times 10^{-7}$
4	$6 \times 10^{-7}$
5	$3 \times 10^{-8}$
Comparative compound (TPCK)	$5 \times 10^{-4}$

This invention is illustrated by the following non-limitative examples:-

Example 1

1-Isopropyl-4-[{4-(1,2,3,4-tetrahydro-1-naphthoyloxy)-  
5 -phenyl} carbamoylmethyl]piperazine.dihydrochloride

1) One hundred milliliters of an ethanol solution containing 7 g of 1-isopropylpiperazine, 6.2 g of ethyl chloroacetate and 9.2 m of triethylamine was heated and refluxed for 4 hours. After being concentrated under reduced pressure, to the resulting mixture was added ethyl acetate. Insoluble matter was removed by filtration. Thereafter, the residue was purified by silica gel chromatography (eluent: a 20:1 mixture of chloroform and methanol) to obtain 7.4 g of 1-ethoxycarbonylmethyl-154-isopropylpiperazine as a light brownish oily substance.

The oily substance thus obtained was dissolved in a solvent consisting of 75 ml of ethanol and 3.5 ml of water, followed by addition of 1.6 g of sodium hydroxide. The mixture was stirred overnight and then neutralized with 20 hydrochloric acid. Insoluble matter was removed by filtration and the residue concentrated under reduced pressure. The resulting oily substance was dissolved in chloroform. The chloroform solution was dried, whereupon the solvent was removed by distillation to obtain 4.76 g of 1-hydroxy-25carbonylmethyl-4-isopropylpiperazine as light brownish powder.

To 6 ml of a chloroform solution containing 559 mg of

the thus obtained compound, 109 mg of p-aminophenol and 36 mg of 4-dimethylaminopyridine, was added 619 mg of dicyclohexylcarbodiimide. The reaction mixture was stirred at room temperature for 2 hours. After being concentrated under reduced pressure, to the resulting mixture was added 10 ml of ethyl acetate. Insoluble matter was removed by filtration, and the residue was extracted with 10 ml of 1N HCl. After being neutralized with sodium hydrogen carbonate, the mixture was extracted with 20 ml of 10 chloroform. The chloroform layer was washed with an aqueous saturated NaCl solution and dried, and the solvent was removed by distillation to obtain 410 mg of a light yellowish substance. Thereafter, the substance was dissolved in 3 ml of methanol, followed by addition of 1.5 15 mg of an aqueous ammonia solution. The resulting mixture was stirred overnight and then concentrated under reduced pressure to obtain 255 mg of 1-(4-hydroxyphenyl)carbamoylmethyl-1-isopropylpiperazine as a yellowish substance.

2) To 10 ml of an ethyl acetate solution containing 20 684 mg of the 1-(4-hydroxyphenyl)carbamoylmethyl-4-isopropylpiperazine obtained in item 1) above, 650 mg of 1,2,3,4-tetrahydro-1-naphthylcarboxylic acid and 45 mg of dimethylaminopyridine, was added 770 mg of dicyclohexylcarbodiimide. The reaction mixture was stirred at room 25 temperature for 2 hours. Insoluble matter was removed by filtration. The residue was extracted with 10 ml of 1N HCl and then neutralized with sodium hydrogen carbonate. After

being washed with water and dried, the resulting mixture was concentrated under reduced pressure to obtain a light yellowish substance. The substance was purified by silica gel column chromatography (eluent: a 20:1 mixture of 5 chloroform and methanol) and dissolved in 20 ml of ethanol. To the ethanol solution was added hydrochloric acid to obtain 684 mg (yield: 54.6%) of 1-isopropyl-4-[{4-(1,2,3,4-tetrahydro-1-naphthoyloxy)phenyl}carbamoyl-methyl]piperazine dihydrochloride as colorless crystals having a melting point of 235 to 240°C (decomposed).

Examples 2 to 7

The procedures of Example 1 were repeated to obtain six compounds of the formula (I), details of which are tabulated in Table 2.





Table 2

Example No.	A	Compound (I)	R	Salt	Yield (%)	Appearance	Heating Point (C)
2	-CH=CH-	-	-CH <sub>2</sub> CH <sub>3</sub>	HCl	61.5	Colorless crystals	207 - 210
3	-	-NHCH <sub>2</sub> CH <sub>2</sub> <sup>-</sup>	-CH <sub>2</sub> CH <sub>3</sub>	-	36.1	Light, yellowish crystals	102 - 103
4	-CH=CH-	-	-CH <sub>3</sub>	(COOH) <sub>2</sub>	72.2	Colorless powdery crystals	146 - 150
5	-	-OCH <sub>2</sub> CO-	-CH <sub>2</sub> CH <sub>3</sub>	HCl	56.8	Colorless crystals	196.5 - 198
6	-CH <sub>2</sub> CH <sub>2</sub> <sup>-</sup>	-	-CH <sub>2</sub> CH <sub>3</sub>	HCl	35.8	Colorless needle-like crystals	169 - 171
7	-CH <sub>2</sub> <sup>-</sup>	-	-CH <sub>2</sub> CH <sub>3</sub>	HCl	56.3	Colorless needle-like crystals	188 - 192

CLAIM

1. Phenyl tetrahydronaphthylcarboxylate derivatives represented by the following formula (I), and pharmaceutically acceptable acid addition salts thereof:-



5 wherein A is a direct bond, or a lower alkylene, vinylene or imino group;

B is a direct bond, a lower alkylene or -NH-lower alkylene group, or an  $-\text{OCH}_2\text{CO}-$  residual group; and

10 R is a lower alkyl group,

with the proviso that A and B are not both direct bonds, and A, B and R are not a lower alkylene group, a direct bond and a methyl group, respectively, at the same time.